ITGAM and neoplasm: To evaluate the roles of the CD11b+Ly6G−Ly6C− MDCs in brain tumor progression, we used an established ALTS1C1-based orthotopic astrocytoma tumor model [38] in CD11b-DTR transgenic mice, with two injections of DT given 11 days post tumor inoculation (Figure 2A).